Indee Labs · Sep 2024
Indee Labs says its Hydropore platform enabled sequential multiplex editing of T cells with improved viability and proliferation versus nucleofection; the post cites planned validation with CellChorus.
Enabling T cell immunotherapy discovery, development and manufacturing
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Indee Labs is a Berkeley-based biotech company building Hydropore™, a patented non-viral microfluidic vortex shedding platform for engineered cell therapies and intracellular delivery into immune cells.
Primary product
Hydropore™ non-viral intracellular delivery platform
Founded
2015
Headquarters
Berkeley, California, United States
Team size
1-10 employees
Work style
Flexible
Industry
Biotechnology Research
Sub-industry
cell therapy tools / non-viral gene delivery
Offices
Berkeley, California, United States
Lindfield, New South Wales, Australia
Business model
B2B research tools
instrument/platform sales
partnered development and co-marketing
distribution
Funding
Stage
Seed stage
Total raised
$5.1M
Latest round
Non-equity Assistance · Jun 2023
Jun 2023 · BioTools Innovator
Apr 2023 · BroadOak BioTools Venture Fund
Sep 2021 · IndieBio / SOSV
Oct 2020 · Pioneer Fund
Aug 2018 · NSW Medical Devices Fund
Jan 2018 · Founders Fund
Jan 2017
People & investors
Leadership
Founder, Chief Executive Officer & Managing Director
Work & culture
Highly collaborative, science-forward, and growth-oriented; company materials emphasize open office hours, cross-functional work, and personal/scientific growth.
Work style
Flexible
Compensation
Public job postings describe competitive compensation with salary and equity; at least one role publicly listed a salary band (e.g. Head of Sales at roughly $135k-$165k base) plus growth opportunities.
Benefits
Unlimited PTO
401(k)
100% paid medical, dental, vision & life insurance
Flexible spending account
Hybrid/remote-friendly work
Snacks
Regular team events
Growth opportunities
Product & market
Pricing
Not publicly disclosed; appears to be B2B platform/instrument sales with partner-led commercialization and early-access/distribution arrangements.
Differentiators
- —Non-viral intracellular delivery via microfluidic vortex shedding
- —Rapid delivery in seconds with minimal impact on viability and function
- —Scales from RUO to cell-therapy manufacturing
- —Works with small molecules, nucleic acids, proteins, and gene-editing complexes
- —ISO 13485-compliant development
- —GMP-grade workflow orientation
- —Small-footprint workflow compared with viral and electroporation systems
Technology
Hydropore™
microfluidic vortex shedding (µVS)
Scispot ELN/LIMS
robotic arms
liquid handlers
Keyence microscopes
GMP-grade buffers
compressed nitrogen
Customers
Three of the top ten pharmaceutical companies
UC San Francisco
Medical University of South Carolina
Stanford
Various biotechnology companies
Competitors
Kytopen
MaxCyte
Lonza Nucleofector
Thermo Fisher Neon
Scale & contact
Estimated revenue
$1M-$10M
Latest news
Indee Labs · May 2023
Announced an exclusive marketing and distribution deal with Sunko Instruments in China for Hydropore.
Indee Labs · May 2023
Indee Labs said Scispot would centralize and automate R&D workflows and help it operate as a digital biotech company.
Indee Labs · Apr 2023
BroadOak BioTools Venture Fund invested to help complete and launch Hydropore RUO and Cell Therapy and a direct DNA knock-in kit.
Indee Labs · Feb 2023
Indee Labs and GenScript partnered to enable larger DNA inserts into immune cells using Hydropore, with co-marketing of a non-viral solution.
Jobs and careers at Indee Labs
0 jobs at Indee Labs
No open positions
Check back later for new openings